Eikonizo Therapeutics
Envisioning an end to neurodegenerative diseases.
Cambridge, United States
13 employees
Total: $40.69M
Biotechnology, Health Care +1
General Information
Cambridge, United States
BounceWatch is an independent company data service, not affiliated with Eikonizo Therapeutics. To contact Eikonizo Therapeutics, visit eikonizo.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Eikonizo Therapeutics compare?
A PDF of Eikonizo Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Eikonizo Therapeutics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Eikonizo Therapeutics
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Early VC | Undisclosed | 1 |
|
01 Dec 2024 |
| Series A | $40.00M | - |
|
01 Dec 2023 |
| Grant | $500.00K | 2 |
Alzheimer’s Association, The Rainwater Charitable Foundation
|
01 Mar 2020 |
| Seed | $190.00K | - |
|
01 May 2018 |
| Spinout | Undisclosed | 2 |
|
01 Apr 2017 |
Eikonizo Therapeutics Alternatives & Competitors
View All Alternatives
Developing a new class of therapeutics for neurodegenerative and psychiatric diseases
Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.
Advancing Accessible Solutions for Complex Neurodegenerative Diseases
FAQ About Eikonizo Therapeutics
Source: BounceWatch company record for Eikonizo Therapeutics, https://bouncewatch.com/company/eikonizo-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.
